Nalmefene

Opioid Overdose Reversal

Nalmefene is primarily used for the emergency treatment of an opioid overdose. It is an opioid antagonist, which means it works by quickly blocking the effects of opioids in the brain. This can help restore normal breathing in someone whose breathing has slowed or stopped due to opioid use. It is effective against various types of opioids, including natural opioids and potent synthetic opioids.

Common Uses

• Emergency Overdose Treatment: It is administered to individuals showing signs of an opioid overdose, such as extreme sleepiness, an inability to wake up, or very shallow breathing.
• Post-Surgical Use: In clinical settings, the injectable form may be used to reverse the effects of opioids that were administered during surgery.

The nasal spray version is indicated for use in adults and pediatric patients aged 12 years and older. Because the effects of some opioids can last longer than the medication itself, emergency medical help must be called immediately after the first dose is given, even if the person appears to recover. Nalmefene is not a substitute for professional emergency medical care.

Mechanism of Action

Nalmefene belongs to a class of drugs known as opioid antagonists. It works by competing with opioid molecules for specific receptor sites in the brain and central nervous system.

During an opioid overdose, drugs such as fentanyl, heroin, or prescription pain medications attach to these receptors, which can cause the body's vital functions to slow down or stop. Nalmefene works through the following process:

• Displacement: It moves into the receptor sites and displaces the opioid molecules that are already there.
• Blocking: Once attached to the receptors, it prevents other opioids from binding to them.
• Reversal: By blocking these receptors, nalmefene helps to temporarily reverse dangerous symptoms such as severely slowed breathing, extreme sleepiness, and low blood pressure.

This medication is specifically designed to restore normal breathing and consciousness in emergency situations involving known or suspected opioid overdoses. Because nalmefene is long-acting, it may stay attached to the brain's receptors for a longer period than some other opioid reversal medications.

Common Side Effects

Some people may experience mild to moderate side effects while using nalmefene. These can include:

• Nausea and vomiting
• Headache
• Dizziness
• Nasal discomfort or irritation (with the nasal spray)
• Fast or irregular heartbeat
• Increased blood pressure
• Feeling hot or flushed
• Chills or fever

Serious Side Effects

The most significant risk associated with nalmefene is the sudden onset of opioid withdrawal symptoms in people who are physically dependent on opioids. These symptoms can be severe and may include:

• Body aches and muscle cramps
• Diarrhea and stomach pain
• Fever, sweating, or shivering
• Runny nose and sneezing
• Goosebumps
• Yawning
• Nervousness, restlessness, or irritability
• Trembling or weakness

If you experience severe symptoms after receiving nalmefene, seek medical attention immediately, as additional treatment may be necessary to manage the withdrawal or the underlying overdose.

Risk of Opioid Withdrawal

In individuals who are physically dependent on opioids, nalmefene can cause sudden and severe withdrawal symptoms. These symptoms may include:

• Nausea, vomiting, and diarrhea
• Increased heart rate and blood pressure
• Sweating, fever, and shivering
• Body aches and tremors
• Anxiety, restlessness, and irritability

In infants, opioid withdrawal can be life-threatening if not recognized and treated properly. Symptoms in neonates may include excessive crying, tremors, and hyperactive reflexes.

Need for Emergency Medical Care

Nalmefene is intended for emergency use and is not a substitute for professional medical care. Emergency services must be contacted immediately after the first dose is administered. While nalmefene has a long duration of action, some opioids may remain in the system longer than the medication, potentially leading to a return of respiratory depression (dangerously slow breathing). The patient must be monitored closely until medical help arrives.

Cardiovascular Risks

The use of nalmefene has been associated with cardiovascular effects such as high blood pressure and a rapid heart rate. These effects may be more significant in patients with known heart disease or those who have recently taken medications that can affect the heart.

Hypersensitivity

This medication should not be used by individuals with a known hypersensitivity to nalmefene or any of its components. Allergic reactions may occur.

Incomplete Reversal

Nalmefene is specifically designed to reverse the effects of opioids. It may not be effective in treating respiratory depression caused by non-opioid substances, such as benzodiazepines, alcohol, or other sedatives.

Pregnancy

There are no adequate and well-controlled studies of nalmefene use in pregnant women. Because human data is limited, it is unknown if nalmefene can cause fetal harm or affect reproductive capacity. In animal studies, high doses of nalmefene did not show evidence of harm to the fetus or impaired fertility.

Nalmefene is primarily used to treat emergency opioid overdose. In these life-threatening situations, the potential benefit of saving a life may justify the unknown risks to the fetus. If you are pregnant or planning to become pregnant, you should discuss the use of this medication with your healthcare provider.

Breastfeeding

It is not known whether nalmefene passes into human breast milk. Because many drugs are excreted in milk, caution is advised when nalmefene is administered to someone who is breastfeeding. If you are nursing, consult with a healthcare professional to discuss the potential risks and benefits to your infant.

Available Forms

Nalmefene is supplied in forms designed for rapid administration during emergency situations:

• Nasal Spray: This is a pre-filled, single-use device used to deliver the medication into the nostril. It is designed for use by bystanders or caregivers in emergency settings.
• Injection: This form is available as a liquid solution for administration into a vein, muscle, or under the skin. It may be provided in vials for use by healthcare professionals or as a pre-filled auto-injector for emergency use.

FDA Approval History

Nalmefene hydrochloride was initially approved by the FDA in 1995 as an injectable medication. While the original injectable version was later discontinued for reasons unrelated to safety or effectiveness, the FDA has recently approved new delivery methods to address opioid overdose.

In May 2023, the FDA approved the first nalmefene nasal spray. This was followed in August 2024 by the approval of a nalmefene auto-injector. Both formulations are indicated for the emergency treatment of known or suspected opioid overdose, characterized by life-threatening respiratory or central nervous system depression.

Approved Indications

The current FDA-approved formulations of nalmefene are intended for use in:

• Adults
• Pediatric patients aged 12 years and older

These products are designed for immediate administration by bystanders or family members in settings where an overdose is suspected. They are not a substitute for professional medical care, and emergency medical services should be contacted immediately after the drug is administered.

Regulatory Status

Nalmefene is classified as an opioid antagonist. Unlike some other overdose reversal agents, nalmefene is currently available only by prescription. There are no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) currently required for nalmefene products.

The FDA notes that nalmefene has a longer duration of action than some other opioid antagonists, which may be beneficial in reversing the effects of long-acting or synthetic opioids. However, because the duration of the opioid may still outlast the nalmefene, continued medical monitoring is essential.

Opioid Withdrawal Symptoms

Nalmefene works by blocking opioid receptors in the brain. In individuals who are physically dependent on opioids, this sudden blockage can trigger acute opioid withdrawal syndrome. These symptoms usually appear within minutes of receiving the medication.

Common signs of withdrawal include:

• Body aches and muscle cramps
• Diarrhea, stomach pain, nausea, and vomiting
• Increased heart rate and high blood pressure
• Fever, sweating, and goosebumps
• Runny nose, sneezing, and yawning
• Restlessness, irritability, or nervousness
• Shivering or tremors
• Weakness

In newborns who have been exposed to opioids, nalmefene can cause severe, life-threatening withdrawal. Symptoms in infants may include excessive crying, tremors, and hyperactive reflexes.